{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:12:50Z","timestamp":1788887570548,"version":"build-2803163510"},"reference-count":50,"publisher":"The Journal of Rheumatology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2019,1]]},"abstract":"Objective.<\/jats:title>Baricitinib is an oral, once-daily selective Janus kinase (JAK1\/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA). We evaluated baricitinib\u2019s safety profile through 288 weeks (up to September 1, 2016) with an integrated database [8 phase III\/II\/Ib trials, 1 longterm extension (LTE)].<\/jats:p><\/jats:sec>Methods.<\/jats:title>The \u201call-bari-RA\u201d group included patients who received any baricitinib dose. Placebo comparison was based on the 6 studies with 4 mg and placebo up to Week 24 (\u201cplacebo-4 mg\u201d dataset). Dose response assessment was based on 4 studies with 2 mg and 4 mg including LTE data (\u201c2 mg-4 mg\u2013extended\u201d). The uncommon events description used the non-controlled all-bari-RA.<\/jats:p><\/jats:sec>Results.<\/jats:title>There were 3492 patients who received baricitinib for 6637 total patient-years (PY) of exposure (median 2.1 yrs, maximum 5.5 yrs). No differences in rates of death, adverse events leading to drug discontinuation, malignancies, major adverse cardiovascular event (MACE), or serious infections were seen for 4 mg versus placebo or for 4 mg versus 2 mg. Infections including herpes zoster were significantly more frequent for 4 mg versus placebo. Deep vein thrombosis\/pulmonary embolism were reported with 4 mg but not placebo [all-bari-RA incidence rate (IR) 0.5\/100 PY]; the IR did not differ between doses (0.5 vs 0.6\/100 PY, 2 mg vs 4 mg, respectively) or compared to published RA rates. All-bari-RA had 6 cases of lymphoma (IR 0.09\/100 PY), 3 gastrointestinal perforations (0.05\/100 PY), 10 cases of tuberculosis (all in endemic areas; 0.15\/100 PY), and 22 all-cause deaths (0.33\/100 PY). IR for malignancies (0.8\/100 PY) and MACE (0.5\/100 PY) were low and did not increase with prolonged exposure.<\/jats:p><\/jats:sec>Conclusion.<\/jats:title>In this integrated analysis of patients with moderate to severe active RA with exposure up to 5.5 years, baricitinib has an acceptable safety profile in the context of demonstrated efficacy. Trial registration numbers:NCT01185353<\/jats:ext-link>,NCT00902486<\/jats:ext-link>,NCT01469013<\/jats:ext-link>,NCT01710358<\/jats:ext-link>,NCT01721044<\/jats:ext-link>,NCT01721057<\/jats:ext-link>,NCT01711359<\/jats:ext-link>, andNCT01885078<\/jats:ext-link>atclinicaltrials.gov<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.171361","type":"journal-article","created":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T00:55:53Z","timestamp":1537059353000},"page":"7-18","source":"Crossref","is-referenced-by-count":237,"title":["Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment"],"prefix":"10.3899","volume":"46","author":[{"given":"Josef S.","family":"Smolen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5294-4503","authenticated-orcid":false,"given":"Mark C.","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Hyslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Riddle Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy E.","family":"Cardillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeko","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2018,9,15]]},"reference":[{"key":"2019010716553446000_46.1.7.1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2019010716553446000_46.1.7.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.10.002"},{"key":"2019010716553446000_46.1.7.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210708"},{"key":"2019010716553446000_46.1.7.4","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902819"},{"key":"2019010716553446000_46.1.7.5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/1744666X.2016.1189826","article-title":"Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis","volume":"12","author":"Iwata","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"2019010716553446000_46.1.7.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1202117"},{"key":"2019010716553446000_46.1.7.7","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2019010716553446000_46.1.7.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"2019010716553446000_46.1.7.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"2019010716553446000_46.1.7.10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019010716553446000_46.1.7.11","first-page":"S51","article-title":"Evaluation of potential drug-drug interactions with baricitinib","volume":"20","author":"Payne","year":"2014","journal-title":"J Managed Care Spect Pharm"},{"key":"2019010716553446000_46.1.7.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206478"},{"key":"2019010716553446000_46.1.7.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150613"},{"issue":"5 Suppl 39","key":"2019010716553446000_46.1.7.14","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2019010716553446000_46.1.7.15","doi-asserted-by":"publisher","DOI":"10.1002\/pds.943"},{"key":"2019010716553446000_46.1.7.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb05705.x"},{"key":"2019010716553446000_46.1.7.17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2019010716553446000_46.1.7.18","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21649"},{"key":"2019010716553446000_46.1.7.19","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"2019010716553446000_46.1.7.20","unstructured":"National Cancer Institute . DCTD, Division of Cancer Treatment and Diagnosis. CTEP, Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, Version 3.0 (CTCAE). [Internet. Accessed July 20, 2018.] Available from: ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"2019010716553446000_46.1.7.21","unstructured":"Howlader N Noone AM Krapcho M Miller D Bishop K Kosary CL Yu M SEER Cancer Statistics Review, 1975\u20132014, National Cancer Institute. [All Cancer Sites (Invasive) Age-Specific SEER Incidence Rates, 2010\u20132014, Table 2.7]. Bethesda, Maryland. Based on November 2016 SEER data submission, posted to the SEER Web site April 2017. [Internet. Accessed July 20, 2018.] Available from: seer.cancer.gov\/csr\/1975_2014"},{"key":"2019010716553446000_46.1.7.22","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) . Guidance for industry on drug-induced liver injury: premarketing clinical evaluation. July 2009. [Internet. Accessed July 20, 2018.] Available from: www.fda.gov\/downloads\/guidances\/UCM174090.pdf"},{"key":"2019010716553446000_46.1.7.23","first-page":"238","article-title":"Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis","volume":"29","author":"Klareskog","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2019010716553446000_46.1.7.24","first-page":"289","article-title":"Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications","volume":"10","author":"Gottlieb","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"2019010716553446000_46.1.7.25","doi-asserted-by":"publisher","DOI":"10.1186\/ar3455"},{"key":"2019010716553446000_46.1.7.26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130683"},{"key":"2019010716553446000_46.1.7.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457"},{"key":"2019010716553446000_46.1.7.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201244"},{"key":"2019010716553446000_46.1.7.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.10524"},{"key":"2019010716553446000_46.1.7.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes305"},{"key":"2019010716553446000_46.1.7.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206028"},{"key":"2019010716553446000_46.1.7.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.074773"},{"key":"2019010716553446000_46.1.7.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"2019010716553446000_46.1.7.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207841"},{"key":"2019010716553446000_46.1.7.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207319"},{"key":"2019010716553446000_46.1.7.36","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong","year":"2007","journal-title":"J Rheumatol"},{"key":"2019010716553446000_46.1.7.37","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40264-016-0430-0","article-title":"Benefit and risk of tofacitinib in the treatment of rheumatoid arthritis: A focus on herpes zoster","volume":"39","author":"Yamaoka","year":"2016","journal-title":"Drug Saf"},{"key":"2019010716553446000_46.1.7.38","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2019010716553446000_46.1.7.39","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2019010716553446000_46.1.7.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208562"},{"key":"2019010716553446000_46.1.7.41","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019010716553446000_46.1.7.42","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"2019010716553446000_46.1.7.43","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137216"},{"key":"2019010716553446000_46.1.7.44","first-page":"614","article-title":"Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme","volume":"35","author":"Curtis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2019010716553446000_46.1.7.45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205847"},{"key":"2019010716553446000_46.1.7.46","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/acr.22039","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2019010716553446000_46.1.7.47","doi-asserted-by":"crossref","unstructured":"Ogdie A Kay McGill N Shin DB Takeshita J Jon Love T Noe MH Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J 2017 Apr 20 (E-pub ahead of print).","DOI":"10.1093\/eurheartj\/ehx145"},{"key":"2019010716553446000_46.1.7.48","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.071244"},{"key":"2019010716553446000_46.1.7.49","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2019010716553446000_46.1.7.50","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) . May 2001. Guidance for industry: E 10 choice of control group and related issues in clinical trials. [Internet. Accessed July 20, 2018.] Available from: www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm073139.pdf"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.171361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T10:35:09Z","timestamp":1720607709000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.171361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,15]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,1]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.3899\/jrheum.171361"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.171361","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,15]]}}}